PCM
IRD

Prelude Capital Management’s Opus Genetics IRD Stock Holding History

Prelude Capital Management’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-12,110
Closed -$15.9K – 1618
2024
Q3 		$15.9K Sell
12,110
-1,742
-13% -$2.68K ﹤0.01% 1236
2024
Q2 		$21.2K Sell
13,852
-6,766
-33% -$11.7K ﹤0.01% 1173
2024
Q1 		$41.4K Sell
20,618
-6,059
-23% -$15.4K ﹤0.01% 1261
2023
Q4 		$80.3K Buy
26,677
+8,681
+48% +$25.7K 0.01% 1045
2023
Q3 		$60.3K Buy
+17,996
New +$72.3K ﹤0.01% 1034
2022
Q3 		– Sell
-17,802
Closed -$34K – 2001
2022
Q2 		$34K Sell
17,802
-10,441
-37% -$23.7K ﹤0.01% 1505
2022
Q1 		$92K Sell
28,243
-24,220
-46% -$82.9K ﹤0.01% 1431
2021
Q4 		$196K Buy
+52,463
New +$210K 0.01% 1577

Other funds holding IRD

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KPWS
Kestra Private Wealth Services Austin, Texas $8.11B AUM 24.74% 1-Year Est. Return

Prelude Capital Management's IRD Position: Q4 2024 in Review

Prelude Capital Management sold out of Opus Genetics (IRD) in Q4 2024, closing a stake of 12,110 shares — an estimated $15.9K sold.

Prelude Capital Management first reported a position in IRD in Q4 2021 and held it in 8 quarters. The position peaked at $196K in Q4 2021. 43 funds tracked by Wall St. Rank hold IRD as of Q4 2024.

  • Prelude Capital Management reported no remaining Opus Genetics position as of Q4 2024 after selling out during the quarter.
  • Prelude Capital Management sold 12,110 Opus Genetics shares in Q4 2024, an estimated $15.9K.
  • Prelude Capital Management first reported a position in Opus Genetics in Q4 2021 and held it in 8 quarters.
  • Prelude Capital Management's Opus Genetics position peaked at $196K in Q4 2021.
  • 43 funds tracked by Wall St. Rank held Opus Genetics as of Q4 2024.

Based on Prelude Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.